Journal
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
Volume 9, Issue 1, Pages 91-97Publisher
WILEY
DOI: 10.1002/acn3.51500
Keywords
-
Categories
Ask authors/readers for more resources
Anakinra may be a therapeutic option for refractory cerebral autoinflammatory diseases, but it may be ineffective for some patients.
Refractory cerebral autoinflammatory-autoimmune diseases are often associated with dysregulated innate immunity and are targeted by anakinra, an interleukin-1 receptor antagonist. We analyzed the therapeutic effect of anakinra in refractory cerebral autoinflammatory response (CAIR) at a single institution from January 2017 to May 2021. In total, 12 patients with various etiologies were sympathetically treated with anakinra (100 mg/day subcutaneously). Four patients showed good responses, and among these patients, three patients had pathologically demonstrated CAIR. The other eight patients were nonresponsive. No patient had a serious adverse effect. Thus, anakinra may be a therapeutic option for refractory cerebral autoinflammatory diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available